### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS

Patricia Anne NUTTALL; Guido Christiaan PAESEN

SERIAL NO.

Not Yet Assigned

**FILED** 

Herewith

FOR

TREATMENT OF ALLERGIC RHINITIS

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

:

Sir:

Prior to calculating the fees pursuant to the entry of the above-identified Application, please amend the Specification and Claims as follows:

# **IN THE SPECIFICATION**:

Please insert the sequence listing into the Application at the end of the Specification and prior to the Claims.

## IN THE CLAIMS:

Please amend Claims 1-8 as follows:

1. (Amended) A method for the treatment or prevention of allergic rhinitis, said method comprising administering to a patient in need thereof, a medicament comprising therapeutically affective amount of a histacalin protein.

- 2. (Amended) A method according to claim 1, wherein said histacalin protein is derived from a blood feeding ectoparasite.
- 3. (Amended) A method according to claim 2, wherein said histacalin protein is derived from a tick.
- 4. (Amended) A method according to claim 1, wherein said histacalin protein is the MS-HBP1, FS-HBP2 or D.RET6 protein, a functional equivalent thereof or an active fragment thereof.
- 5. (Amended) A method according to claim 1 wherein a pharmaceutically-acceptable excipient is also used in the manufacture of the medicament.
- 6. (Amended) A method according to claim 1, wherein one or more antihistamine agents or anti-sedative agents is also used in the manufacture of the medicament.
- 7. (Amended) A method of treating or preventing allergic rhinitis comprising administering to a subject a histacalin protein as described in claim 1 or a pharmaceutical composition as described in claim 5 in a therapeutically-effective dosage.
- 8. (Amended) A method according to claim 7, wherein said allergic rhinitis is seasonal or perennial allergic rhinitis.

## **REMARKS**

The above amendments are submitted in order to enter the sequence listing into the Application and to reduce multiple dependencies and to conform the claims more closely to U.S. practice.

Entry of the foregoing amendments and early and favorable processing in the National Phase before the United States Patent and Trademark Office is courteously solicited.

Respectfully submitted,

DAVID A. TACKSON Attorney for Applicant(s) Registration No. 26,742

KLAUBER & JACKSON 411 Hackensack Avenue Hackensack, NJ 07601 (201) 487-5800

## **VERSION WITH MARKINGS TO SHOW CHANGES MADE**

### IN THE CLAIMS:

Claims 1-8 have been amended as follows:

- 1. (Amended) A method [Use of a histacalin protein (as defined above) in the manufacture of a medicament] for the treatment or prevention of allergic rhinitis, said method comprising administering to a patient in need thereof, a medicament comprising therapeutically affective amount of a histacalin protein.
- 2. (Amended) A method [Use] according to claim 1, wherein said histacalin protein is derived from a blood feeding ectoparasite.
- 3. (Amended) <u>A method</u> [Use] according to claim 2, wherein said histacalin protein is derived from a tick.
- 4. (Amended) <u>A method</u> [Use] according to claim 1, wherein said histacalin protein is the MS-HBP1, FS-HBP2 or D.RET6 protein, a functional equivalent thereof or an active fragment thereof.
- 5. (Amended) A method [Use] according to [any one of] claim[s] 1 [to 4] wherein a pharmaceutically-acceptable excipient is also used in the manufacture of the medicament.
- 6. (Amended) A method [Use] according to [any one of] claim[s] 1[ to 5], wherein one or more antihistamine agents or anti-sedative agents is also used in the manufacture of the medicament.

- 7. (Amended) A method of treating or preventing allergic rhinitis comprising administering to a subject a histacalin protein as described in [any one of] claim[s] 1 [to 4,] or a pharmaceutical composition as described in [either one of] claim[s] 5 [and 6] in a therapeutically-effective dosage.
- 8. (Amended) [Use according to any one of claims 1 to 6 or a] A method according to claim 7, wherein said allergic rhinitis is seasonal or perennial allergic rhinitis.